Literature DB >> 32913003

Distinct financial distress profiles in patients with breast cancer prior to and for 12 months following surgery.

Raymond Chan1,2, Bruce Cooper3, Steven Paul3, Yvette Conley4,5, Kord Kober3, Bogda Koczwara6, Alexandre Chan7,8, Chia Jie Tan9, Louisa Gordon10, Lebogang Thomy2, Jon Levine11, Christine Miaskowski12.   

Abstract

BACKGROUND: Study purposes were to identify subgroups of patients with breast cancer with distinct self-reported financial distress (FD) profiles and determine which demographic, clinical and symptom characteristics, as well as quality of life (QOL) outcomes were associated with subgroup membership.
METHODS: Patients (n=391) who were assessed for changes in FD a total of 10 times from prior to through 12 months after breast cancer surgery. Latent profile analysis was used to identify subgroups of patients with distinct FD profiles.
RESULTS: Three distinct FD profiles (ie, None (14.6%), Low (52.7%), High (32.7%)) were identified. Compared with None and/or Low subgroups, patients in the High subgroup were more likely to report a lower annual household income and performance status; had a higher body mass index, axillary lymph node dissection and more advanced stage disease; had a longer time from cancer diagnosis to surgery; and had received neoadjuvant or adjuvant chemotherapy. In addition, patients in the High subgroup reported higher fatigue, sleep disturbance, state/trait anxiety, depressive symptom scores, and lower attentional function and QOL scores.
CONCLUSION: This study provides new insights on risk factors for and evidence of a higher symptom burden associated with FD. Findings from this study provide clinicians with information on how to identify high-risk patients and to recommend appropriate interventions for both symptom management and FD. Additional research on the mechanisms that underlie the relationships among FD and common physical and psychological symptoms may inform future interventions. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  breast; symptoms and symptom management

Mesh:

Year:  2020        PMID: 32913003     DOI: 10.1136/bmjspcare-2020-002461

Source DB:  PubMed          Journal:  BMJ Support Palliat Care        ISSN: 2045-435X            Impact factor:   4.633


  4 in total

1.  Telehealth cancer-related fatigue clinic model for cancer survivors: a pilot randomised controlled trial protocol (the T-CRF trial).

Authors:  Rahul Ladwa; Elizabeth P Pinkham; Laisa Teleni; Brigid Hanley; Gemma Lock; Jodie Nixon; Oluwaseyifunmi Andi Agbejule; Fiona Crawford-Williams; Lee Jones; Mark B Pinkham; Jane Turner; Patsy Yates; Steven M McPhail; Joanne F Aitken; Carmen P Escalante; Nicolas H Hart; Raymond J Chan
Journal:  BMJ Open       Date:  2022-05-16       Impact factor: 3.006

2.  Partnering with general practitioners to optimize survivorship for patients with lymphoma: a phase II randomized controlled trial (the GOSPEL I trial).

Authors:  Raymond Javan Chan; Stephanie Buhagiar; Laisa Teleni; Camilla Simonsen; Jane Turner; Courtney Rawson; Nicolas H Hart; Lee Jones; Louisa Gordon; Ria Joseph; Oluwaseyifunmi Andi Agbejule; Fiona Henderson; Joel Rhee; Marissa Ryan; Christine Carrington; Sally Mapp
Journal:  Trials       Date:  2021-01-06       Impact factor: 2.279

3.  Rethinking the Meaning of "Wellness" for a Person with Cancer: A Qualitative Study to Explore What Elements Constitute "Wellness".

Authors:  Jodie Nixon; Raymond Chan; Emma McKinnell; Elizabeth Ward; Elizabeth Pinkham; Laurelie Wishart; Elizabeth Miller; Bena Brown
Journal:  Asia Pac J Oncol Nurs       Date:  2021-05-22

4.  Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery.

Authors:  Raymond Javan Chan; Bruce Cooper; Louisa Gordon; Nicolas Hart; Chia Jie Tan; Bogda Koczwara; Kord M Kober; Alexandre Chan; Yvette P Conley; Steven M Paul; Christine Miaskowski
Journal:  BMC Cancer       Date:  2021-08-02       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.